Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
08:30am, Sunday, 05'th Mar 2023
GSK's RSV vaccine candidate could prevent deaths and hospitalizations in older patients. The product could end up generating over $1 billion in annual revenue for the company.
March 2023 Stock Considerations
03:46am, Saturday, 04'th Mar 2023
2023 is flying by as two months are already in the books and that fact simply highlights to me the importance of staying invested in the stock market during the good times and bad. VZ stock is trading
GSK neck and neck with Pfizer in the race to get first RSV jab to market
05:19am, Thursday, 02'nd Mar 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine has been endorsed by advisors to the US Food & Drug Administration, who assessed its safety and efficacy in older adults. The d
FDA advisory panel votes in favor of adult RSV vaccine from GSK PLC
03:18pm, Wednesday, 01'st Mar 2023
CNBC's Meg Tirrell joins 'Power Lunch' to discuss GSK PLC's RSV vaccine receiving FDA support, ongoing questions around the drug's approval and the timeline for the drug to be available for children.
FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks
02:33pm, Wednesday, 01'st Mar 2023
The Food and Drug Administration's independent panel of advisors on Wednesday recommended GlaxoSmithKline's RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over n
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults
02:15pm, Friday, 24'th Feb 2023
The FDA sees a potential risk and has asked Pfizer to conduct a safety study on Guillain-Barre after a potential approval, which the company said it would do.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Friday, 17'th Feb 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?
11:21am, Wednesday, 15'th Feb 2023
Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now?
Dividend Income Update: January 2023
07:30am, Monday, 13'th Feb 2023
Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality.
Dividend Income Summary: Lanny's January 2023 Summary
06:01am, Saturday, 11'th Feb 2023
Investing in dividend stocks allows you to earn dividend income, the best passive income stream. Dividend Income is the fruit from the labor of investing your money in the stock market.
GSK cancer drug gets the FDA green light
02:59am, Friday, 10'th Feb 2023
GSK PLC (LSE:GSK, NYSE:GSK) said that the US Food and Drug Administration (FDA) has granted full approval for Jemperli, a drug for the treatment of mismatch repair-deficient endometrial cancer in adul
Is Biotech Immunocore About To Make A 25% Price Move?
07:00am, Tuesday, 07'th Feb 2023
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc
GSK's Innovative Specialty Products Need More Insurance Coverage, Still A Buy
01:33am, Friday, 03'rd Feb 2023
Rukobia is a bright spot, but it's a pill, thus enjoying almost universal coverage. Kaiser Permanente recognizes their worth.
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
06:04pm, Thursday, 02'nd Feb 2023
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
